-+ 0.00%
-+ 0.00%
-+ 0.00%

Can-Fite reports positive Phase 2a data for namodenoson in pancreatic cancer trial

PUBT·04/30/2026 12:41:02
Listen to the news
Can-Fite reports positive Phase 2a data for namodenoson in pancreatic cancer trial
  • Can-Fite BioPharma reported positive Phase 2a data for namodenoson in advanced pancreatic cancer.
  • Study results have already been presented in part, with full top-line efficacy analyses slated for presentation at a future clinical conference in coming months.
  • Trial showed signs of durable disease control in heavily pretreated patients, supporting continued development in pancreatic cancer.
  • Can-Fite highlighted extended time on therapy for several patients, with 35% still receiving treatment.
  • Safety profile remained favorable, consistent with prior reports.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Can Fite Biofpharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604300831PRIMZONEFULLFEED9710471) on April 30, 2026, and is solely responsible for the information contained therein.